

Subject Index

BR: Book review; CR: Conference report

Conferences are listed under an entry 'Conferences' and not individually.

A

- A86281, psoriasis treatment 227–228
- Abciximab 557, 558, 559
- Abgenix, research agreement 79
- Absorbance, assay imaging 408
- Absorption, distribution, metabolism and excretion (ADME) 535
- ABT299, platelet activating factor antagonist 218
- Academia
- applied projects 488–489
 - role and collaboration with industry 487–489
- Acetylcholine
- nicotinic receptor *see* Nicotinic receptors
 - role in Alzheimer's disease (CR) 150
- ACT496 MOS system 266–267
- Acute-phase proteins, synthesis, Alzheimer's disease 277–278
- Acyclic nucleoside phosphonates (ANP)
- antiviral action 97
 - immunomodulatory and pharmacological profile 97–98
- Addiction, cocaine *see* Cocaine abuse
- Adefovir 97
- Adenine derivatives, inhibition of LPS-induced signal transduction 217
- Adenosine
- interaction with GABA receptors 549
 - opioid receptors interaction 549
- Adenosine A₁-receptor antagonist, non-xanthine 333–334
- Adenosine receptors
- cardiovascular system 544–546
 - central nervous system and 546–548
 - in endotoxaemia 542–543
 - inflammatory/immune response 542–544
 - pain transmission 548–549
 - as potential therapeutic targets 542–551
 - renal system 546
 - respiratory disease 543–544
 - subtypes 542
- Adenosine triphosphate (ATP), analogues 239
- Adenovirus, lacking E1B (ONYX-015) 462
- ADEPT therapy, carboxypeptidase G₂ inhibitors 334
- ADME, discovery–development interface and 535
- β₂-Adrenoceptor agonists, with dopamine D2-receptor agonists 140
- α₁-Adrenoceptor antagonist 440–441
- Adriamycin, drug-sensitive/-resistant breast cancer cells 33
- Adverse drug reactions
- burden in future (CR) 393
 - causes and mortality (CR) 200–201
- Aequorea victoria* 304
- green fluorescent protein *see* Green fluorescent protein (GFP)
- AIDS
- antisense oligonucleotide therapy (Vitravene™) 4–5
 - see also* HIV
- Algène Biotechnologies Corporation, strategic alliance 342
- Alignment algorithm, sequence database searching 483
- Allergic reactions, eotaxin 91
- AlliedSignal, co-marketing alliance 342
- Alzheimer's disease 149–151
- acetylcholine role (CR) 150
 - animal models 279–280
 - COX-2 inhibitors 280
 - development risk, anti-inflammatory agent effects 275
 - genetic factors 275–276
 - 5-HT-receptor agonists treatment 142
 - IL-6 inhibitors 280
 - inflammatory mechanisms 276–279
 - neuropathology 276
 - new therapy 275–282
 - nicotinic drugs 490, 491
 - pharmacogenomics paradigm (CR) 106
 - risk factors (CR) 149–151
 - steroidal drugs 280
 - therapy developments (CR) 149–151
- Amersham Pharmacia Biotech
- collaboration deal 349
 - co-marketing alliance 342
- γ-Aminobutyric acid *see* GABA receptors
- 5-Aminolaevulinic acid, photosensitizer 510–511
- Amodiaquine, novel antimalarials based on 569
- Amoxicillin, selection patents 315
- AMPA-receptor antagonists 569
- β-amyloid, in Alzheimer's disease 276, 277
- conference (CR) 149
- β-amyloid precursor protein 171
- in Alzheimer's disease 277
- Anaesthetics, inhalation, chiral switches 316
- Androgen-receptor agonist, nonsteroidal, novel 238–239, 386
- Angiogenesis inhibitor, spinal cord injury treatment 53
- Angiotensin-converting enzyme (ACE), selective inhibitors 482
- Animal models 15
- Alzheimer's disease 279–280
 - hypertension 244
 - see also* Mouse models
- Animal tests, flow cytometry 179–180
- Animal varieties, European Biotechnology Directive 30–31
- Anisotropy
- binding reactions monitored by 357–359
 - fluorescence 356–357
- Anti-AP1 specific agents 224
- Antibacterial agents
- novel 140, 186
 - see also* Antibiotics
- Antibacterial disaccharides, combinatorial chemistry 570–571
- Antibiotic peptides
- activity and susceptibility improvement 256
 - design 256
 - eukaryotic 254–256
 - evolutionary aspects 254
 - mechanisms of action 255, 256
 - protease inhibitor and (CR) 397–398
 - role in health/disease 254–255
 - specificity and pathogen resistance 255–256

- Antibiotic resistance 345
 - effect of antibiotics on development 72–79
 - molecular infidelity 77–78
 - molecular redundancy 73–77
 - efflux-mediated 74
 - multiple, antibiotic-induced 74
 - phenotypic, antibiotic-induced 74
- Antibiotics
 - as anthropogenic pheromones 75
 - antiproteasomal 190–191
 - company collaboration 376
 - DNA transmission/release 74–75
 - gene transfer induced by 73
 - mutagenesis stimulated by 77
 - new agents under development 396–397
 - novel 140, 186
 - novel fluoroquinolones 93
 - polyketide synthases role in development 345–346
 - resistance caused by 72–79
 - stress perpetuated by 77
 - superdrugs (CR) 395–398
 - targeted programs 395–396
 - use in proteomics 132
 - vectors for antibiotic resistance 75–76
- Antibodies
 - high-throughput technology 536
 - lipopolysaccharide 212–213, 214
- Antibody-direct enzyme prodrug therapy (ADEPT), carboxypeptidase G₂ inhibitors 334
- Anticancer therapy *see* Antitumour agents
- Anti-CD4, antibodies 229
- Anti-cocaine agents 328–330, 429
 - (correction)
 - see also* Dopaminergic agents
- Antidepressants
 - novel 5-HT_{1A}-receptor agonists 142–143
 - US market 332
- Antifolate drugs
 - in cancer therapy (BR) 492–494
 - efficacy (BR) 493
- Antifungal drugs
 - computer-aided target selection 17–26
 - current drug targets, assessment 21–22
 - identification of new targets 24
 - target proteins, assessment 22–24
- Antigen presentation
 - modulation by proteasome inhibitors 63–71
 - lactacystin 67–68
 - peptide-derived inhibitors 68–69
 - proteasome action 191
- Antihyperglycaemic agents
 - see* Hypoglycaemic agents
- Antihypertensive therapy, in Alzheimer's disease (CR) 151
- Anti-inflammatory drugs
 - Alzheimer's disease therapy 275–282
 - immunosuppressants as 472
 - psoriasis 223
- Anti-inflammatory strategies
 - gene-regulating protein kinases as targets 472–479
 - against lipopolysaccharide 217–218
- Anti-lipopolysaccharide factors 213
- Antimalarial drugs
 - discovery 147 (corrigendum)
 - erratum 44
 - novel 568–569
- Antimicrobial peptides
 - see* Antibiotic peptides
- Antimicrobials
 - RNA targets 425–426
 - see also* Antibiotics; Antifungal drugs; Antiviral agents
- Antimycobacterial agents 480–481
- Anti-osteoporotic agents 335
- Antioxidants
 - neuroprotection (CR) 49
 - prevention of tissue damage caused by lipopolysaccharide 218
- Antiplatelet therapies 552–561
 - agents 554
 - ideal agent 554
 - in ischaemic diseases 554–555
 - see also* GPIIb/IIIa-receptor antagonists
- Antiproteasomal antibiotics, lactacystin 190–191
- Antisense DNA, gene therapy with (BR) 9
- Antisense oligodeoxynucleotides 460–461
- Antisense oligonucleotides
 - clinical trials 563
 - concept, role, benefits and testing 4–5
 - drug delivery 5
 - FDA approval 4
 - functional genomics 564
 - genetic pathway elucidation 566
 - high-throughput approach 562–567
 - nuclease resistance 5
- Antisense technology 562–563
- Antithrombotic therapy
 - GPIIb/IIIa-receptor antagonists 557
 - see also* GPIIb/IIIa-receptor antagonists
 - novel 239
- Antitumour agents
 - cell cycle inhibitors 462–463
 - CM101 and application for spinal injuries 53
 - natural 39
 - novel 481–482
 - plastics (CR) 540–541
 - thioester derivatives of leinamycin 384
 - see also* Cancer therapy; Chemotherapy
- Anti-ulcer drugs, chiral switches 319–320
- Antiviral agents
 - hepatitis C virus 518–529
 - immunomodulatory 97–98
- Anxiety disorders
 - novel 5-HT_{1A} receptor agonists 142
- AP-1 transcription factor
 - antagonists 224
 - inhibition 93–94
- Apoptosis
 - nitric oxide mechanisms (CR) 48
 - proteasome inhibitors effect 191
- Apoptotic protease activating factor-1 570
- Appetite suppressant, chiral switches 320
- Architecture, workplace design 181–185
- Area under curve (AUC)
 - determination methods 234–235
 - rapid pharmacokinetic screening of discovery compounds 232–237
- Arginine vasopressin, receptor antagonists 530
- Arteriosclerosis
 - chemokine receptor role (CR) 300
 - prevention 460
- β-(Arylsulfonyl)hydroamic acid 291
- Ascomycin, derivatives 227–228
- N-Aspartyl chlorine 515
- Aspartyl proteases, inhibitors (CR) 539
- Aspirin 191–192, 552–561
- Assays, screening and imaging systems 401–410
 - see also* Image-based screening

- Assay techniques, new (CR) 251–253, 410
(corrigendum)
- Asthma
chemokines role (CR) 300
emerging therapies 291
eotaxin receptor and 91
mechanisms 291
phosphodiesterase inhibitors 40
- Atherosclerosis, cell cycle drugs 458
- Atomic force microscopy, combinatorial
approach (CR) 538–539
- Attention deficit hyperactivity disorder
(ADHD), nicotinic drugs 490, 491
- Attrition rate, conference (CR) 343
- Autoimmune disorder, psoriasis 222–223
- Automated synthesis
conference (CR) 8
in organic chemistry 265–274
compound factories 272–273
impact on laboratory synthesis
273–274
method development and research
273
miniaturization trends 273
modular systems 270–271
non-robotic fluidic systems
269–270
personal tools 272
purification tools 271–272
reaction-block systems 265,
266–268
robot-arm systems 268–269
tools 265–274
organic compounds 399–400
- Automation
combinatorial chemistry, conference
(CR) 343
combinatorial chemistry and molecular
diversity (BR) 203
convergent parallel synthesis
377–383
design in organic chemistry 265–266
flow cytometry 174, 177
miniaturization and 341–342
miniaturized FRET-based assays
368–369
synthetic laboratory 380–381
- AVI BioPharma, research agreement 79
- Awards, Bristol-Myers Squibb Foundation
237
- Azole antifungals, target protein
assessment 22–24
- B**
- Bactericidal permeability-increasing protein
(BPI) 213–214
- Bacteriochlorins 516
- Bafilomycin A₁ derivatives 168–169
- Bafilomycins
derivatives 169–170
osteoclast V-ATPase inhibitor 165
- BAYx3702, novel 5-HT_{1A}-receptor agonist
142
- Benzimidazole derivatives, osteoclast
V-ATPase inhibition 167
- 1,4-Benzodiazepine-2,5-dione libraries 141
- Benzothiazole derivatives, osteoclast
V-ATPase inhibition 167
- Benzoxazole derivatives,
osteoclast V-ATPase inhibition 167
- Benzotropine 327–328, 429 (correction)
- β-turn mimics, combinatorial libraries 141
- Biacore, product development 551
- BIBU52 558
- BIBU104 (lefradafiban) 558, 560
- Bicyclic guanidines, libraries 187
- Binding assays, flow cytometry comparison
176, 177
- Bioactive metabolites, produced from
microbial fermentation (CR) 450–451
- 'Bioavailability wall' 537
- Biodiversity
increased using plant cultures (CR)
449–450
natural products (CR) 449–451
- Bioinformatics 240–243, 482–484
antifungal drugs 17–18
databases 43–44
evaluating software 240–243
in genomics (CR) 52
new knowledge bases 42–43
toxicology and pharmacokinetics (CR) 200
use in proteomics 133
value-added databases 42
see also Databases
- Biological materials, patentability, Europe 29
- Biological simulation, drug discovery 10–16
- Biology, combinatorial approach (CR)
538–540
- Bioluminescence, assay imaging 406–407
- BioMedNet 197
- Biopharmaceutical industry, intelligence
systems 206–207
- Biophotonics, molecular (CR) 348–349
- BioRegio concept 302
- BioResearch Ireland 303
- Biosensors
enhanced green fluorescent protein
(EGFP) 308–309
green fluorescent protein (GFP) 307
novel DNA detection methods 346–348
- Biotechnology industry
corporate intelligence 204–208
in Europe (CR) 301–303
see also European biotechnology
geographical clusters 297–298
global products 297–298
information needs 204–205
- Biotechnology patents *see* Patents
- Biotechnology platforms 207–208
- Biotransformation
metabolism databases and 466–471
see also Metabolism databases
- Bisphosphonates 166
- BLAST algorithm 483
- Bleeding, risk with GPIIb/IIIa-receptor
antagonists 560
- Bleomycin, secondary effects 75
- Boehringer Ingelheim, research
collaboration 342
- Bone
drug-related structural changes 443–444
metabolism 443–444
mineral maturation 443–444
resorption, inhibitors, drug targets 163
- Bone morphogenetic proteins (BMP) 472,
475
- Bone morphogenetic proteins (BMP)
receptor kinases 475
- Book reviews
Antifolate Drugs in Cancer Therapy
(Jackman) 492–494
Clinical Trials of Genetic Therapy with
Antisense DNA and DNA vectors
(Wickstrom) 9
Combinatorial Chemistry and Molecular
Diversity in Drug Discovery (Gordon
and Kerwin) 203
Combinatorial Chemistry (Terrett) 54
Medicinal Plants of the World (Ross) 154
Peptidomimetic Protocols in the series
Methods in Molecular Medicine
(Kazmierski) 454
- Bottlenecks
high-throughput screening (HTS) 1–2
R&D in 2005 (CR) 393–394
- Bradykinin, antagonist 214

- Breast cancer
 cyclin D1 as therapeutic target 458, 459
 CYCLIN D1 gene expression 458
- Bristol-Myers Squibb
 agreement 439
 strategic collaboration 471
- Bristol-Myers Squibb Foundation, award 237
- BRL48482, non-thiazolidinedione insulin sensitizer 285
- BRL49653, solid-phase synthesis 336
- Bromocriptine 325
- BTERT* 157, 158
- Bupropion 326
- Business strategies 198
- C**
- Calcipotriol 223
- Calcitriol, psoriasis treatment and 223
- Calcium, intracellular, measurements 433
- Calcium channel blockers, N-type 39, 335–336
- Cameras, image-based screening 403
- CaNa₂ EDTA 533
- Cancer
 cell cycle disease 458
 cell cycle molecules as drug targets 458
 p53 importance 457
 plastics therapy (CR) 540–541
 susceptibility with cell cycle gene aberrations 458, 459
 telomerase action 156–157
 see also Tumours
- Cancer Gene Anatomy Project (CGAP) 118–119
- Cancer therapy
 antifolate drugs (BR) 492–494
 enzyme for increased susceptibility 250–251
 molecular targets 96
 phosphatidylinositol-3-kinase as target 96
 photodynamic therapy 507–517
 tumour resistance, organelle pH role 32–38
 see also Antitumour agents;
 Chemotherapy
- Candida albicans*
 computer-aided drug target selection 17–26
 proteomics application 57
- Cantab Pharmaceuticals, anti-cocaine vaccine 376
- CAP18, lipopolysaccharide inactivation 213
- Carboxypeptidase G₂, novel inhibitors 334
- Cardiac arrhythmia
 adenosine receptors and 544–545
 models 11
- Cardiac ischaemia, adenosine receptors and 545–546
- Cardioprotection, adenosine receptor activation 545–546
- Cardiovascular disease
 antiplatelet agents 555
 cell cycle drugs 458–459
 GPIIb/IIIa-receptor antagonist therapy 558–559
- Cardiovascular system
 adenosine receptors 544–546
 nitric oxide imbalance 243–244
- Caspase-3 538
- Caspase fusion protein, for HIV resistance 202
- Catabolic states, proteasome inhibitor action 192
- Catabolism, growth hormone secretagogues 503–504
- Catalysts, novel, combinatorial approach (CR) 539
- Cathepsin D inhibitors 95
- Cathepsin K, osteoporosis drug target 441–442
- Cationic antimicrobial protein (CAP18) 213
- CATS (computer-aided target selection), antifungal drugs 17–26
- CC chemokine family 81
- CCR chemokine family
 CCR1 antagonists 89
 CCR1 in disease 89
 CCR2 antagonists 89–91
- CD4, antibodies, in psoriasis 229
- CD11a, antibodies, in psoriasis 229
- CD14
 antibodies 214
 lipopolysaccharide-binding molecule 219
 lipopolysaccharide clearance 213
 as new antifungal drug target 24
- CD28 (CTLA4-Ig), in psoriasis 229
- CDNA libraries, normalized, Merck Gene Index project (MGIP) 118
- Cell-based assays
 green fluorescent protein (GFP) applications 304–312
 ion-channel targets 431–439
 miniaturized FRET-based assays and 363–369
- Cell cycle
 blockers 191
 in cancer 458
 conventional drug therapy and 462–463
 drug discovery and 455–464
 drug target 457–458
 gene aberrations and cancer susceptibility 458, 459
 molecules as drug targets 457–458
 validation as drug targets 460–463
- Cell cycle kinases, inhibitors 462
- Cell death
 nitric oxide-induced damage (CR) 48
 see also Apoptosis
- Cell lines, human, collections 152
- Cellular screening assays, flow cytometry 174–175
- Central nervous system, adenosine receptors and 546–548
- Cerep, strategic collaboration 471
- Cerus, public offering of stock 152
- Cervical cancer, treatment trial 567
- Chemiluminescence
 assay imaging 406–407
 high-throughput assay (CR) 349
- Chemistry, combinatorial approach
 see Combinatorial chemistry
- Chemokine(s) 80
 classification 80–84
 conference (CR) 299–300
 intracellular signalling 85–86
 ligands and properties of 82
 role in infectious disease 87–88
 role in inflammatory disease 86–91
 structure (CR) 299
- Chemokine receptors
 antagonists 89–91
 CCR1 89
 CCR2 89–91
 CCR7 (CR) 299
 comparisons 84–86
 conference (CR) 299–300
 ligand binding sites 84–85
 novel therapeutic agents acting at 80–92
 structure 84–85

- Chemotaxis, chemokine action 80
- Chemotherapeutics 33
- Chemotherapy 33
- antifolates (BR) 493–494
 - drug-sensitive and drug-resistant cells 33–34
 - exocytosis of drugs 35
 - new (CR) 250–251
 - pH effect on distribution of drugs 34–35
 - telomerase as target 155–160
 - see also* Antitumour agents; Cancer therapy
- Chip-based screening devices 341
- Chips, functional genomics 52
- Chirality of drugs, intellectual property 313–321
 - see also* Chiral switches
- Chiral molecules, kinetic resolution by libraries 41
- Chiral selectors, library 41
- Chiral stationary phases 95
- Chiral switches 313
 - fluoxetine hydrochloride 318–319
 - ibuprofen 317–318
 - inhalation anaesthetics 316
 - omeprazole 319–320
 - patent law precedents 315–316
 - selection invention 314–315
- Chiron Corporation, hepatitis C virus technology lawsuit 495
- Cholesterol-lowering agents 139
- Cholesterol-modifying agents 139
- Chromatography, multidimensional, use in proteomics 132
- Chromophore, green fluorescent protein 304–305
- Ciglitazone 284
- CL184005, platelet activating factor antagonist 218
- Clinical information, medicinal plants (BR) 154
- Clinical trials
 - gene therapy with antisense DNA and DNA vectors (BR) 9
 - growth hormone secretagogues 502
 - phase I, nitric oxide neutralizing compound 9
 - photosensitizers 509, 513
- Clontech Laboratories, reverse transcriptase patent lawsuit 495
- Clopidogrel 555
- Clusters, geographical
 - biotechnology 297–298
 - Europe 302–303
- CM101, paralysis prevention 53
- CMV *see* Cytomegalovirus (CMV)
- Coagulation, lipopolysaccharide-activated, inhibition 216
- Cocaine 322
 - analogues 328–329, 429 (correction)
 - craving 322
 - vaccine trial 376
- Cocaine abuse
 - dopamine hypothesis 322–323, 429 (correction)
 - treatment with dopaminergic agents *see* Dopaminergic agents
- Collaborations 198
 - functional genomics 113
 - industrial-academic 487–489
- Colorectal cancer, NB1011 therapy 185
- Combinatorial chemistry 377, 398–400
 - antibacterial disaccharides 570–571
 - approach to biology/chemistry (CR) 538–540
 - bicyclic guanidine libraries 187
 - β -lactams 570
 - book review (BR) 54
 - cathepsin D inhibitors 95
 - fibrinogen receptor motif 386
 - flavone benzodiazepine receptor ligands 187
 - glycopeptide libraries 240
 - high-affinity SH2-targeted ligands 442
 - high-loading single resin beads 41
 - information needs of biotechnology industry 204–205
 - integration into drug discovery process (CR) 7–9
 - kinetic resolution by libraries 41
 - medicinal chemistry synergy (CR) 7–9
 - microdispensing applications 418–419
 - molecular diversity and (BR) 203
 - NMR-based screening 532
 - novel antitumour agents 481–482
 - novel approaches for the new millennium 1–2
 - novel catalysts (CR) 539
 - novel chiral stationary phases 95
 - novel protein kinase inhibitors 336
 - number of leads 447–448
 - oestrogen receptor ligands 442
 - κ -opioid-receptor antagonist libraries 239
 - origins and flexible approach 399
 - D-peptide antigens 292
 - peptidomimetic protocols (BR) 454
 - peptidyl trifluoromethyl ketones 291
 - polyketides 345–346
 - PPAR γ agonist optimization 239–240
 - pressures in R&D process 3
 - protein farnesyltransferase inhibitors 95–96
 - RAS farnesylation inhibition 336–337
 - sarcodictyin libraries 141
 - in silico* screening approach 257–264
 - solid-phase synthesis of BRL49653 336
 - tetanus toxin inhibitors 291–292
 - thymidylate synthase inhibitors 442–443
 - traditional drug discovery methods vs (CR) 199
 - virtual 257–263
 - widening of range (CR) 538–540
- Combinatorial genomics, novel compound isolation from marine organisms (CR) 450
- Combinatorial libraries
 - 1,4-benzodiazepine-2,5-dione 141
 - bicyclic guanidines 187
 - β -turn mimics 141
 - cathepsin D inhibitors 95
 - design 447–448
 - glycopeptides 240
 - high-loading single resin beads 41
 - kinetic resolution by 41
 - knowledge-based (CR) 539
 - multi-target 187–188
 - new screening methodology 386–387
 - novel antitumour agents 481–482
 - κ -opioid antagonist 239
 - D-peptide antigens 292
 - protease inhibitors 387
 - RAS proteins 336–337
 - sarcodictyin 141
 - screening (BR) 203
 - split-mix 539
 - virtual 571
- CombiTec system 267
- Complement
 - activation in Alzheimer's disease 279
 - lipopolysaccharide-activated, inhibition 216
- Computational drug discovery 447
- Computational library screening 571
- Computer-aided analysis, yeast genome 18

- Computer-aided target selection (CATS)
 antifungal drug discovery 17–26
 in context of drug discovery 25
 data generation and analysis 18–21
 scoring parameters 18–21
 updates and improvements 25
- Computer simulation
 in drug discovery 10–16
 peptide/protein folding 153
- Computer software
 bioinformatic 241
 evaluation 240–243
 Diverser 257–264
 drug target selection, antifungal drug
 discovery 17–26
 for image-based screening 404–405
- Concanamycins, osteoclast V-ATPase
 inhibitor 165
- Conferences
 Accelerating preclinical development by
 successful integration into drug
 discovery 452–453
 Bio '98 International on
 pharmacogenomics 105–107
 Biotech Europe '99 301–302
 Chemokines and their receptors
 299–300
 Combinatorial approaches to chemistry
 and biology 538–540
 Drug Discovery Technologies '99
 343–345
 Drug Discovery Technology '99
 Exposition and Symposium 249–250
 Euroconference on nitric oxide 47–49
 Functional Genomics: Strategies and
 Enabling Technologies for Target and
 Drug Discovery 50–53
 IBC conference on pharmacogenomics
 6
 IBC's 8th annual conference on HTS
 251–253, 410 (corrigendum)
 Integrating Combinatorial Chemistry into
 the Drug Discovery Pipeline 7–9
 Molecular Labels, Signalling and
 Detection 346–349
 pharmacokinetics and toxicology
 screening 199–201
 Pharma Directions '99 393–395
 plastics in cancer therapy 540–541
 Profiting from biodiversity by leveraging
 natural product drug discovery
 449–451
- Royal Society of Chemistry 538–540,
 540–541
 Superbugs and superdrugs: innovations
 in anti-infectives 395–398
 The Therapeutic Era (Alzheimer's
 disease) 149–151
- Consortia, discovery–development
 interface 535
- Convergence, automated parallel synthesis
 377–383
- Corporate intelligence, in biotechnology
 204–208
- Correlation spectroscopy, fluorescence
 359–362
- COX-1 inhibitors 140
- CP0127, bradykinin antagonist 214
- CTLA4-Ig, psoriasis treatment 229
- CXC chemokine family 80–81
- Cyclic AMP, phosphodiesterase 4 (PDE4)
 inhibitor 40
- Cyclin-dependent kinases 455–457
 antisense oligodeoxynucleotides and
 460–461
 inhibitors 462
 peptides inhibiting 461
 purine inhibitors 482
- Cyclins 455–457
- Cyclohexenones, trans-trisubstituted,
 convergent automated parallel
 synthesis 382
- Cyclooxygenase-2 (COX-2)
 expression in Alzheimer's disease
 278–279
 selective inhibitors 334–335
- Cyclooxygenase inhibitors
 Alzheimer's disease 280
 selective, 4,5-diarylimidazoles 140
- Cyclopentenones 335
- Cyclosporin, psoriasis treatment 226–227
- Cysteinyl leukotriene D₄-receptor
 antagonists 40
- Cystic fibrosis, pharmacogenomics (CR)
 105–106
- Cystic fibrosis transmembrane conductance
 regulator (CFTR) (CR) 105
- Cytochrome P450
 polymorphism and adverse drug
 reactions (CR) 200
 profile, proteomics application 61–62
- Cytokines
 gene expression activation by acyclic
 nucleoside phosphonates 97–98
- gene therapy 291
 immunomodulatory, asthma treatment
 291
 response to lipopolysaccharide 211
 inhibition 217–218
 synthesis, Alzheimer's disease 277–278
- Cytokine-suppressive anti-inflammatory
 drugs (CSAID)-binding protein (CSBP)
 289
- CytoMed, sale to LeukoSite 172
- Cytomegalovirus (CMV)
 antisense oligonucleotide therapy
 (Vitravene™) 4–5
 chemokine receptor 87
 chemokines and (CR) 300
- Cytotoxic T cells, antigen presentation and
 proteasome inhibitors 63–71
- D**
- DAB₃₈₉ IL-2, psoriasis treatment 228
- Daptomycin 396
- Data
 access in R&D databases 371–375
 analysis, software packages (CR) 253
 diversity 257–263
 integration technology 372
 management, software packages (CR)
 253
 mining 371–372
- Databases
 accessing and information sharing 372,
 494–495
 bioinformatic software 241
 biological, simulation in drug discovery
 and 14–15
 of databases 43–44
 diversity 257–263
Drug Discovery Today online 197
 expressed sequence tag (EST) 121
 genomics (CR) 52
 high-throughput screening (HTS)
 370–376
 information needs of biotechnology
 industry 204–207
 Merck Gene Index project (MGIP) 115
 metabolism *see* Metabolism databases
 new knowledge bases 42–43
 predictive 468–470
 proteomics 130
 sequence, rapid searching 482–483
 value-added 42
see also Bioinformatics

- Data coded by location (DCBL) 258–263
- Decision support, lead portfolio 371–375
- Delphi Report on Knowledge Management* 494–495
- 3-Deoxy-D-manno-octulosonic acid 212
- Depression
 - novel 5-HT_{1A}-receptor agonists 142
- Derwent Information, patent information access 451
- Desflurane, chiral switches 316
- Design, workplace and innovation 181–185
- Destruxins, osteoclast V-ATPase inhibitor 165
- Dexfenfluramine 320
- Dexibuprofen 318
- Diabetes mellitus
 - gastric emptying control 290
 - insulin resistance improvement 283–286
 - oral hypoglycaemic agents
 - see Hypoglycaemic agents
 - type 2, PPAR γ agonists 239–240
- 4,5-Diarylimidazoles 140
- Diastereomeric interactions 318
- Digitization, knowledge (report) 494–495
- Dihydrofolate reductase inhibitors, erratum 44
- 1,25-Dihydroxyvitamin D₃ 223
- DIIM, indole sub-structure 469
- Dimethylsulfoxide (DMSO) 367–368
- Diphtheria toxin 228
- Directives see European Biotechnology Directive
- Dispensary, outsourced 400
- Diversa Corporation, technology exchange 383
- Diverser software 257–264
- Diversity
 - analysis 257–264
 - data 257–263
 - see also Biodiversity
- DMP728, GPIIb/IIIa-receptor antagonist 557
- DMP754 558, 560
- DNA
 - detection, novel methods (CR) 347–348
 - human, patenting (Europe) 29–30
 - microchip-based detection (CR) 346–347
 - repair, enzyme to increase susceptibility to chemotherapy 250–251
 - sequences, patenting 135
 - shotgun sequencing of human genome 136
 - transmission/release induced by antibiotics 74–75
 - vectors, genetic therapy with (BR) 9
- DNA array technology, toxicology use (CR) 199
- DNA-ligase IV 441
- DNA-protein complex, HIV reverse transcriptase 108
- Docetaxel, mechanism of action 462
- Dolasetron 469
- Dopamine hypothesis, cocaine abuse 322–323, 429 (correction)
- Dopamine receptors
 - agonists 324, 429 (correction)
 - antagonists 324, 429 (correction)
 - D1-family of ligands 324–325, 429 (correction)
 - D2-family of ligands 325, 429 (correction)
 - D2-receptor agonists, β_2 -adrenoceptor agonists with 140
 - D3-receptor antagonists 569–570
 - D4-receptor, pyrazoles as novel ligands 93
 - ligands 324, 429 (correction)
- Dopaminergic agents, cocaine abuse treatment 322–332, 429 (correction)
- antagonists and agonists 324, 429 (correction)
- pathway and intervention points 323–324, 429 (correction)
- specific agents 324–330, 429 (correction)
- Dopaminergic pathways 324–325, 429 (correction)
- Dopamine transporters (DAT) 323, 429 (correction)
- ligands 326, 429 (correction)
- Dose range, toxicology study (CR) 201
- Doxorubicin, HPMA-copolymer conjugate (CR) 540–541
- DP protein 457, 461
- Drosomycin 256
- Drosophila*, antibiotic peptide action 255
- Drug(s)
 - absorption prediction (CR) 452
 - assessment, simulations and models 10–16
 - candidates, evaluation, simulations 13–14
 - chirality and intellectual property 313–321
 - mode of action, proteomics application 59–61
 - non-responders (CR) 106
 - permeability prediction (CR) 452
 - single enantiomer 313–316
 - small-molecule, binding to RNA 420–422
 - solubility prediction (CR) 452
 - testing, antisense oligonucleotides 4
- Drug delivery, antisense oligonucleotides 5
- Drug design
 - peptide/protein folding simulations and 153
 - polymorphic sites and 151
 - rational 257–263
- Drug development
 - nicotinic drug advances 491–492
 - pharmacogenetics 151–152
- Drug discovery
 - acceleration and novel approaches for new millennium 1
 - benefits of miniaturization and UHTS 341–342
 - biological simulation 10–16
 - combinatorial chemistry and molecular diversity (BR) 203
 - computational 447
 - conference (CR) 249–250
 - flow cytometry 173–180
 - genomic technologies, IBC conference (CR) 6
 - overstated effectiveness of technologies 447
 - proteomics role 55–62
 - telomerase inhibitors 155–161
 - see also specific subjects
- Drug discovery–development interface 535–536
- Drug Discovery Today*
 - new editor and novel approaches for new millennium 1–2
 - objectives (1999) 2
 - online access 197
- Drug metabolism pharmacokinetic studies (DMPK)
 - conference (CR) 452–453
 - rapid pharmacokinetic screening of compounds, *in vivo* 232–237
- Drug metabolizing enzymes, polymorphisms 151

- Drug resistance
 HIV 201–202
 reversal strategy by blocking organelle acidification 36
 tumours, organelle pH role 32–38
see also Antibiotic resistance;
 Multidrug resistance (MDR)
- Drug targets
 adenosine receptors 542–551
 antisense oligonucleotides validation 562–567
 candidate, proteomics assessment 58
 cell cycle 457–458
 computer-aided selection, antifungal drug discovery 17–26
 flow cytometry role 179
 functional genomics and (CR) 50–53
 genes 103–104
 phosphatidylinositol-3-kinase in cancer 96
 RNA 420–422
 simulations for drug discovery 13
 telomerase 155–160
 validation *see* Validation
see also Emerging molecular targets;
specific targets
- Drug toxicology *see* Toxicology
 'Drug universe' 447
 DT5461, lipopolysaccharide antagonist 214, 215
- E**
- E2F transcription factor 461
 importance in cell cycle 457
- E5531, lipopolysaccharide antagonist 214, 215
- Editorials
 biotechnology clusters 297–298
 discovery–development interface 535–536
 genomics and proteomics 103–104
 industrial–academic collaboration 487–489
 ion-channel modulators 391–392
 novel approaches for new millennium 1–2
 number of leads from HTS 447–448
 pharmaceutical industry and paradoxes in R&D progress 198–199
 rewards of new technologies 341–342
- Elderly, growth hormone secretagogues 503
- Electrophysiology, ion-channel modulators 391–392
- Elongation factor 3, yeast, drug target 21
- ELR chemokine subfamily 80–81
- Emerging molecular targets
 apoptotic protease activating factor-1 570
 cathepsin K 441–442
 DNA-ligase IV 441
 mast cell tryptase inhibitors 441
- Emerging technologies
 accelerated toxicity evaluation (CR) 453
see also New technology
- Enantiomer, patent specification 316
- Endothelins
 ET_A-receptor antagonists 440
 ET_B-receptor antagonists 139–140
- Endotoxaemia 212, 542–543
- Endotoxic shock *see* Septic shock
- Endotoxin *see* Lipopolysaccharide
- Endotoxin-neutralizing protein (ENP) 213
- Energy transfer, fluorescence resonance
see Fluorescence resonance energy transfer (FRET)
- Enzymes
 increased susceptibility to chemotherapy 250–251
 polyketide synthases 345–346
- Eosinophils, eotaxin role in recruitment 91
- Eotaxin
 active/inactive (CR) 299
 eosinophil recruitment 91
 receptor
 in asthma 91
 conference (CR) 300
 role (CR) 300
- Epidermal growth factor (EGF) receptors, antagonist as natural antitumour agent 39
- Epigenetics, antibiotic resistance 72–79
- Eptifibatide 558
- Escherichia coli*, vaccine (CR) 397
- Estrogen receptors, ligand displacement assays (CR) 252
- Ethical issues, European Biotechnology Directive 30
- Ethnic groups, drug design and 151
- Eukaryotes
 antibiotic peptides *see* Antibiotic peptides
 cell cycle 455–456
- Europe, patent law for chiral switches 316
- European biotechnology 297–298, 301–303
 case studies and initiatives (CR) 302
 management and patent issues (CR) 301–302
 market potential (CR) 303
 state of industry (CR) 301
- European Biotechnology Directive 27–31
 ethical and moral issues 30
 first proposed directive 27–28
 introductory paragraphs 28–29
 plant and animal varieties 30–31
 provisions 29–31
 second proposed directive 28
- European Union (EU), directive 98/44/EC 27–31
- Evolution
 antibiotic peptides 254
 antibiotic resistance 72–79
- EVOTEC BioSystems, antibiotic collaboration 376
- Excitotoxicity
 inducible nitric oxide synthase (iNOS) 292–293
 measurement (CR) 200
- Exocytosis, chemotherapeutic drug 35
- Expressed sequence tags (EST)
 Merck Gene Index project (MGIP) 115–122
 patents 136
- F**
- F11440, novel 5-HT_{1A} receptor agonist 142
- 'Farmer's privilege', European Biotechnology Directive 30–31
- FASTA algorithm 483
- Fermentation, bioactive metabolites produced from (CR) 450–451
- Fibrinogen receptor, new motif 386
- First-in-man (FIM) study (CR) 201
- FK506 (tacrolimus), psoriasis treatment 227
- Flaviviridae, hepatitis C virus 518–529
- Flavone benzodiazepine receptor, ligands 187
- Flavopiridol, mechanism of action 462
- Flow cytometry
 automation 174, 177
 cellular screening assays 174–175
 comparison with other techniques 177–179
 conference (CR) 348

- in drug discovery 173–180
- future prospects 179–180
- genome analyses 176–177
- instrumentation 173
- microsphere agents 174
- microsphere arrays 177
- molecular interactions *in vitro* studies 175–176
- sample handling 173–174
- Fluidic systems, non-robotic 269–270
- Fluorescence
 - assay imaging 407–408
 - blue, cyan and yellow proteins 305–306
 - flow cytometry 173
 - green fluorescent protein *see* Green fluorescent protein (GFP)
 - homogeneous readouts for miniaturized HTS 350–362
 - macromolecular property prediction 353–354
 - miniaturization and 341
 - principles and descriptors 350–353
 - probes (CR) 348–349
- Fluorescence anisotropy (polarization) 356–357
- Fluorescence correlation spectroscopy 359–362
- Fluorescence resonance energy transfer (FRET) 354–356
 - 3456-well assay plates 366
 - assays 364–365
 - conference (CR) 251–252
 - G-protein-coupled receptor assay 367
 - ion-channel target assays 434–435
 - miniaturized assays 363–369
 - protease assay 365
- 5-Fluorocytosine, target protein assessment 24
- Fluoroquinolone antibiotics, novel 93
- Fluorous-phase chemistry, purification method (CR) 8
- Fluoxetine 142
- Fluoxetine hydrochloride, chiral switches 318–319
- Fluphenazine 325
- Fomiversen sodium, FDA approval 4
- Food and Drug Administration (FDA)
 - antisense oligonucleotide approval 4
 - on hepatitis B vaccine 253, 282
- Free-format assays 408–409
- FRET *see* Fluorescence resonance energy transfer (FRET)
- Functional genomics 109–114
 - antisense 564–566
 - antisense oligonucleotides and 564
 - applications to pharmaceutical R&D 109
 - collaboration versus in-house technologies 113
 - conference (CR) 344
 - investments 111
 - market opportunities (CR) 50–51
 - outlook for future 113
 - scientific and technology challenges 111–113
 - strategic considerations 110–111
 - strategies and technologies (CR) 50–53
- Functional profiling, of genes 112
- Fungal cell wall proteins, drug target 22
- Fungal diseases, cell cycle drugs 459
- G**
- GABA receptors
 - adenosine interaction 549
 - GABA_A receptor, high-affinity ligands 334
- β-Galactosidase, transduced, activity 537
- Galkapagos Genomics NV, new company 264
- Gamma-aminobutyric acid *see* GABA receptors
- Gamma vinyl-GABA 330
- Gastric emptying, control 290
- Gastric secretion, histamine H₃ receptors and 571–572
- Gastrointestinal tract, histamine H₃ receptors and 571–572
- GBR12909 326
- GBR derivatives, analogues 327
- Gel Tech, joint venture 143
- Gene(s)
 - coverage in Merck Gene Index project (MGIP) 120
 - discovery
 - as drug targets 103–104
 - human disease 123–128
 - disease
 - discovery using mouse models 123–128
 - identification 121
 - enhancer/suppressor 127
 - functional profiling 112
 - functions, determination (CR) 51–52
 - human homolog identification 121
 - identification, human diseases 123–127
 - mapping, Merck Gene Index project and 121
 - patenting, human genome 115
- Gene expression
 - differential, genomics use 121
 - Merck Gene Index project (MGIP) 115–122
 - serial analysis (CR) 51
 - toxicology and (CR) 200
- Genentech, collaborative agreement 94
- Gene polymorphisms, drug design and 151
- Gene therapy
 - antisense DNA and DNA vectors (BR) 9
 - cytokines 291
 - for HIV resistance 202
 - nitric oxide synthase strategies (CR) 49
- Genetics, mouse 123–127
- Genetic systems, model (CR) 51
- Genetic therapy *see* Gene therapy
- Gene transcription *see* Transcription
- Gene transcripts, Merck Gene Index project (MGIP) 115–122
- Gene transfer
 - antibiotic-induced 73
 - cell cycle targets 461–462
 - horizontal, antibiotic resistance 73–74
- Genistein 476
- Genome
 - analyses, flow cytometry 176–177
 - Saccharomyces cerevisiae* 17–18
- Genome Pharmaceuticals Corporation, antibiotic collaboration 376
- Genomics 103–104, 129
 - business aspects (CR) 50
 - combinatorial 450
 - conference (CR) 249, 344
 - in drug discovery and development (CR) 6
 - drug target development 14
 - functional *see* Functional genomics
 - future developments 137–138
 - 5-HT₃ receptor roles 114
 - impact on proteomics 62
 - intellectual property rights 134–138
 - Merck Gene Index project *see* Merck Gene Index project (MGIP)
 - microdispensing applications 417–418
 - new molecular targets 3
 - pharmacogenomics comparison (CR) 105
 - toxicology and (CR) 200

- Genset, strategic alliance 342
- Gensia Sicor Pharmaceuticals,
development and supply contract
lawsuit 495
- Geographical clusters, biotechnology
297–298
- Glibenclamide 287
- Glycopeptides, combinatorial libraries
240
- GP1515, signal transduction inhibitor 216
- GPC AG, research collaboration 342
- GP1Ib/IIIa-receptor antagonists 552–561
actions 555–556
acute therapy with 558–559
adverse effects and monitoring
560–561
chronic therapy 559–560
classes 555, 556
comparative antiplatelet effects
556–557
drug interactions 561
small-molecule 559
- G-protein-coupled receptors (GPCRs)
chemokine receptors comparisons
84–86
FRET assay 367
- G-quadruplex interactive agents,
telomerase inhibition 158–159
- Gram-negative bacteria,
lipopolysaccharides
see Lipopolysaccharide
- Grants, academics 487
- Green fluorescent protein (GFP)
applications in cell-based assays
304–312
biosensors 307
chromophore 304–305
conference (CR) 252
enhanced (EGFP) 305, 307
biosensors 308–309
destabilized 308–309
future prospects 311
high-content screening 309–311
protein localization monitoring 309
red-shifted variants 305
as transcription reporter 306–308
variants 304
- Growth hormone
deficiency 497, 503
release
acute 502
compounds stimulating 497–506
- Growth hormone-releasing peptides
(GHRP) 497, 502
- Growth hormone secretagogues 497–506
central actions 501
clinical indications/studies 502–504
pharmacology 500–501
specificity 501
structure 498
- Guanidines 187
- Guanylate cyclase, soluble (sGC), nitric
oxide target (CR) 48
- GumTech International, joint venture 143
- ## H
- Haloperidol 325
- Heart, models for simulations in drug
discovery 10–16
- Helicase, hepatitis C virus 524–525
- Helicobacter pylori* 571–572
- Hepatitis, non-A non-B (NANBH) 518
see also Hepatitis C virus (HCV)
- Hepatitis B virus (HBV) vaccine, FDA
request 253, 282
- Hepatitis C virus (HCV) 518–529
current therapies 518–519
helicase inhibitors 524–525
internal ribosomal entry sites (IRES)
inhibitors 525–527
NS3 protease 521–524
polymerase and inhibitors 527
research problems 519–520
technology, lawsuit 495
- Heuristic algorithms, sequence database
search programs 483–484
- Hexarelin, growth hormone secretagogue
502
- Hexose-related imidazolidinones 480
- High-content screening, green fluorescent
protein 309–311
- High-loading single resin beads
41
- High-throughput approach, antisense
oligonucleotides 562–567
- High-throughput assays, ion-channel
modulators 391–392
- High-throughput methods, functional
genomics and 112
- High-throughput purification and analysis,
combinatorial chemistry (CR) 7–9
- High-throughput screening (HTS) 398–400
antibodies 536
antifungal drugs 17–26
- automated synthesis 265–274
in organic chemistry
see Automated synthesis
synthesizers 266
- combinatorial chemistry conference
(CR) 7
- databases 370–376
- developments (CR) 249
- green fluorescent protein and 309–311
- imaging systems 401–410
- ion-channel targets 431–436
- microdispensing applications 415–417
- miniaturized, homogeneous
fluorescence readouts 350–362
- natural products (CR) 451
- new frontiers for 21st century (CR)
251–253, 410 (corrigendum)
- novel approaches for new millennium 1
- number of leads 447–448
- occlusion ('bottleneck') 1–2
- pharmacokinetic and metabolic (CR)
452–453
- purification tools 271–272
- RNA as small-molecule drug target
423–425
- ultra-HTS see Ultra-high-throughput
screening (uHTS)
- Hirudin, actions 557
- Histamine H₃-receptors 571–572
antagonists 568
functions 571–572
- HIV
drug resistance
gene therapy to overcome 202
new protease inhibitor for 201–202
protease, drugs targeting 387–388
receptors, coreceptors 87–88
TAT protein 537, 538
X-ray crystallography of reverse
transcriptase 107–108
- Homogeneous binding assays 177
- HPMA copolymers 540–541
- Human Genome Organization (HUGO) 121
- Human Genome Project 109, 115, 136,
564–566
- Merck Gene Index project (MGIP)
115–122
- progress and commercial implications
(CR) 50
- shotgun sequencing 136–137
- Human materials, patenting (Europe)
29–30

- Human papillomavirus (HPV) infection, cell cycle molecules 458–459
- Hybridization, flow cytometry 177
- Hydrazones, substituted 539
- 3-Hydroxy-3-methylglutaryl co-enzyme A reductase (HMGCoA), inhibitors 139
- 7-Hydroxy-DPAT 325
- Hydroxymethotrexate, book review 493–494
- 5-Hydroxytryptamine (5-HT) receptors 142
- 5-HT_{1A}, role in depression and anxiety 142
- 5-HT_{3A} 114
- 5-HT₃ receptors 114
- 5-HT₆ receptor antagonist 238
- 5-HT receptor agonists, Alzheimer's disease treatment 142
- h5-HT₁₀ receptor agonists 333
- tetrahydrobenzindoles as selective 5-HT₇-receptor antagonists 290
- Hypericin, photosensitizer 516
- Hypertension, animal models 244
- Hypoglycaemic agents
- oral 283–288
- insulin sensitizers *see* Insulin sensitizers
- non-sulfonylurea insulinotropic agents 286–288
- (3-substituted benzyl)thiazolidine-2,4-diones 335
- I**
- Ibogaine 329–330
- Ibuprofen, chiral switches 317–318
- IκB kinases 474
- conference report (CR) 252
- I.M.A.G.E. data 117
- Image-based screening 401–410
- applications 405–409
- components 402–405
- Imidazolidinones, hexose-related 480
- Immune defence, antibiotic peptides and 254–255
- Immune response 542–544
- to lipopolysaccharide 210
- Immunomodulatory agents, antivirals 97–98
- Immunophenotyping 174–175
- Immunoprecipitation, proteomics application 59
- Immunosuppressants
- as anti-inflammatory drugs 472
- psoriasis treatment 226–228
- Immunosuppression
- protein kinase inhibitors 478–479
- selective proteasome inhibitors 63–71
- IMPDH inhibitors, psoriasis treatment 228
- Imperial College of Science and Technology and Medicine 464
- Indole ring
- drugs with 469
- metabolism 468, 469
- Indolocarbazole derivatives 166
- Industrial–academic collaboration 487–489
- Industrial revolution, in pharmaceutical industry, report 3
- Industry forecasts, PricewaterhouseCoopers report 3
- Infections
- chemokines role 87–88
- Gram-negative bacteria and endotoxins *see* Lipopolysaccharide
- RNA targets 425–426
- Inflammation 542–544
- chemokine role (CR) 299–300
- Inflammatory disease, chemokines role 86–91
- Influenza, sialidase inhibitor 531
- Informatics, conference (CR) 344
- Information
- compound portfolio reports 374
- explosion caused by combinatorial chemistry (CR) 8–9
- needs of biotechnology industry 204–205
- sharing and enhancing (report) 494–495 *see also* Bioinformatics; Databases
- Information technology, conference (CR) 344
- Infrared microspectroscopy, drug-related structural changes to bone 443–444
- Inherited diseases, mouse models 124–125
- Innovation, workplace design and 181–185
- Inorganic pyrophosphatase, as new antifungal drug target 24
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, psoriasis treatment 228
- In silico* modelling, drug
- absorption/permeability prediction (CR) 452
- In silico* screening 257–264
- Insulinotropic agents, non-sulfonylurea 286–288
- Insulin resistance, improvement in diabetics 283–286
- Insulin secretagogues 286–288
- Insulin sensitizers 283–286
- non-thiazolidinedione 284–286
- thiazolidinedione 283–284
- Integrilin 558, 559
- α₄β₁ Integrin inhibitors 186
- Intellectual property
- chirality of drugs and 313–321
- European Biotechnology Directive 27–31
- private sector strategy 135–136
- rights, genomics 134–138 *see also* Patents
- Intelligence digests, biotechnology information 205–206
- Intelligence systems, biopharmaceutical industry 206–207
- Interfacial phenomena, discovery–development 535–536
- Interferon, hepatitis C virus therapy 518–519
- Interleukin-1 (IL-1), response to lipopolysaccharide 217
- Interleukin-2 (IL-2), DAB₃₈₉ IL-2 fusion protein 228
- Interleukin-6 (IL-6)
- response to lipopolysaccharide 217
- secretion inhibitor 385
- synthesis inhibition, Alzheimer's disease therapy 280
- transgenic animals expressing 278
- Interleukin-8 (IL-8)
- antibodies, in psoriasis 229
- chemokine action 82, 83
- in inflammatory disease 86–87
- inhibition 87
- Interleukin-9 (IL-9), asthma pathogenesis 291
- Interleukin-converting enzyme (ICE) inhibitors, combinatorial chemistry (CR) 8
- Internal ribosomal entry sites (IRES) hepatitis C virus 525–527
- inhibitors 525–527
- Internet
- compound portfolio management and 371–372
- computer-aided drug target selection and 17–18

- Drug Discovery Today* 197
- information sharing and distribution 494–495
- sequence database search programs 483–484
- Intestinal motility, histamine H₃-receptors and 572
- Intracellular signalling, chemokines 85–86
- Intranets, compound portfolio reports 374
- IntroGene BV, joint venture 264
- Inventiveness, patentability of chiral switches and 314
- Invitrogen Corporation, technology exchange 383
- Ion channels
- activity measurement 435–436
 - modulators 391–392
- Ion-channel targets
- cell-based assays 431–439
 - screening 431–439
- Ipamorelin, growth hormone secretagogue 502
- Ischaemic diseases, antiplatelet agents 554–555
- Ischaemic heart disease, antiplatelet agents 555
- Isis Pharmaceuticals, antisense oligonucleotide approval 4
- Isoflurane, chiral switches 316
- Isoquinolinol, aminomethyl-substituted derivatives 39
- Isozymes 470
- ISRA system 269
- J**
- Janus-associated kinases (JAKs) 472, 475
- JTT501, non-thiazolidinedione insulin sensitizer 285
- K**
- Ketolides 397
- Kinase, new inhibitors 289
- Kinase assays, techniques (CR) 252–253
- Kinetic analyses, flow cytometry 176
- Kinetic resolution, of chiral molecules by libraries 41
- Kinins, inhibition of cascade activated by lipopolysaccharide 214
- Kisliuk effect 493
- Knowledge
- accessing and information sharing 494–495
 - bases 42–43
 - management, report 494–495
 - pyramids 205–206
- Knowledge-based libraries, conference (CR) 539
- Knowledge-based systems, metabolism databases 466–468
- L**
- L161240, lipopolysaccharide synthesis inhibition 212
- L167307, serine/threonine kinase inhibitor 477
- L692429, growth hormone secretagogue 502
- L734005, indole sub-structure 469
- Laboratory building, innovative design 181–182
- Lactacystin
- antiproteasomal antibiotic 190–191
 - selective proteasome inhibitor 67–68
- β-Lactams, combinatorial synthesis 570
- Lamifiban 558
- Large protein therapeutics 537–538
- applications 537–538
 - protein activity retention 537
- Lawsuits
- development and supply contract 495
 - hepatitis C virus technology 495
 - reverse transcriptase enzyme patents 495
- Lead compounds, metabolic databases and 466
- Lead optimization
- book review (BR) 54
 - discovery–development interface 535
 - new technologies (CR) 199
- Lead portfolio
- decision making and analysis 371–375
 - intranet-based reports 374
- LEADseeker™ 404, 406, 407
- Lefradafiban 558, 560
- Leinamycin, thioester derivatives 384
- Leukocyte, trafficking, chemokines role (CR) 299
- Leukocyte elastase, inhibitors 481
- LeukoSite, company acquisition 172
- Leukotriene B₄-receptor antagonist, in psoriasis 229
- Leukotriene D₄-receptor antagonists 39–40
- Life Technologies, reverse transcriptase patent lawsuit 495
- Ligand binding, ion-channel modulators 392
- Ligands, dopamine receptor 324, 429 (correction)
- Light-based probes, conference (CR) 348–349
- Linezolid 397
- Lipid A 209, 215
- biosynthesis 214
- Lipid IV_A 214, 215
- Lipid-lowering agents 139
- Lipid mediators, inhibition of LPS-induced signal transduction 217
- Lipid modifying agents 139
- Lipid X 214, 215
- Lipopolysaccharide 209
- antagonists 214
 - antibodies 212–213, 214
 - anti-inflammatory strategies against 217–218
 - binding to receptors, prevention 214
 - cascade of responses to 210–212
 - circulating, neutralization 212–214
 - detoxification/removal 212
 - disorders mediated by 209–221
 - host components neutralizing/binding 213–214
 - inhibition of bacterial synthesis/release 212
 - plasma cascades 210–212
 - inhibition 214–216
 - receptors 219
 - signal transduction inhibitors 216–217
 - strategies against tissue damage 218
- Lipopolysaccharide-binding molecules, CD14 219
- Lipopolysaccharide-binding protein 210, 213, 219
- Lipoproteins, lipopolysaccharide inactivation 213
- Lisofylline, signal transduction inhibitor 216
- Lotrafiban 558, 560
- LPS *see* Lipopolysaccharide
- Ludvig Institute for Cancer Research 349
- Luteinizing hormone releasing hormone, receptor antagonist 94
- Lymphocyte migration patterns, chemokine role (CR) 299

M

- Macrolides 397
- Macrophage, response to
 - lipopolysaccharide 210
- Macrophage metalloelastase, inhibitors 481
- Magainin Pharmaceuticals, collaborative agreement 94
- Maitake Products, mushroom products 192
- Major histocompatibility complex (MHC), class I assembly pathway 63–65
- Malaria, proteasome inhibitors action 192
- Management
 - European biotechnology (CR) 301
 - people (CR) 394
- MAP kinase 472, 473–474
 - inhibitors 476–477
 - new inhibitors 289
- Marine natural products, HIV protease targeted 387–388
- Marine organisms, novel compound isolation (CR) 450
- Markets
 - potential (CR), European biotechnology 303
 - US growth of antidepressant market 332
- Mass spectrometry
 - drug discovery and (CR) 343–344
 - pharmacokinetic screening of discovery compounds 232
 - proteomics 56, 130
- Mast cell tryptase inhibitors 441
- Matrix metalloproteinases (MMP)
 - dual inhibition with phosphodiesterase type 4 inhibitors 290–291
 - inhibitors 533
 - novel inhibitors 385
- Mazindol 326
- MDL201112, signal transduction inhibitor 216
- Medeva plc, FDA advice for 253, 282
- Medicinal chemistry
 - combinatorial chemistry synergy (CR) 7–9
 - peptidomimetic protocols (BR) 454
- Medicinal plants, book review (BR) 154
- Medinox, phase I clinical trial of nitric oxide neutralizing compound 9
- Meglitinide 287
- MEK inhibitors 93–94
- Membrane, antibiotic peptide interactions 255
- Membrane potential, measurement 392, 433–434
- Merck Gene Index project (MGIP) 115–122
 - coverage of genes 120
 - data analysis 119–120
 - goals 115–116
 - philosophy 117–118
 - scientific plan 118–119
 - utility of gene sequences 120–122
- Mergers 198
- Metabolism 466
 - defining rules 470
- Metabolism databases 466–471
 - knowledge-based systems 466–468
 - new directions 470–471
 - predictive 468–470
- Metalloenzymes, nitric oxide target (CR) 48
- Metalloproteinase inhibitors 532
 - natural 532–533
 - synthetic 533
- Methicillin-resistant *Staphylococcus aureus* (MRSA) 395
 - new antibiotics for 396–397
- 18-Methoxycoronaridine 330
- 4'-Methylene-10-deazaminopterin (MDAM), book review 493–494
- Methylene blue, photosensitizer 510
- Methylphenidate 326–327
- Mice
 - knockout, cyclins 456, 458
 - see also* Mouse models
- Microarrays
 - detection/reading (CR) 347
 - functional genomics (CR) 52
 - microdispensing applications 417–418
- Microbial fermentation *see* Fermentation
- Microdispensing technologies 411–419
 - applications 413–419
 - Inkjet 412
 - pin-transfer 412–413
 - practical issues 413–415
- Microfluidics, miniaturization and 342, 363–369
- Microglial activation
 - in Alzheimer's disease 276–277
 - reduction in Alzheimer's disease therapy 280
- Microplate assays, flow cytometry comparison 177
- Microsphere arrays, flow cytometry 177
- Microspheres, development, flow cytometry 174
- Miniaturization
 - benefits 341–342
 - FRET assays 363–369
 - HTS 350–362
 - image-based screening 401–410
 - techniques (CR) 252–253
 - trends, automated synthesis in organic chemistry 273
- Mitogen-activated protein (MAP) 94
- Mitogen-activated protein (MAP) kinase *see* MAP kinase
- MK0677, growth hormone secretagogue 502
- MKC242, novel 5-HT_{1A}-receptor agonist 142
- Modelling
 - biological processes in drug discovery 10–16
 - drug absorption/permeability prediction (CR) 452
- Models
 - animal 15
 - biological simulations in drug discovery 10–16
 - genetic systems (CR) 51
 - mouse *see* Mouse models
- Molecular diversity
 - analysis 257–264
 - combinatorial chemistry and (BR) 203
- Molecular dynamics, peptide folding 153
- Molecular interactions, *in vitro* studies using flow cytometry 175–176
- Molecular labels, conference (CR) 346–349
- Molecular pharmacological tools, novel (CR) 6
- Monocyte chemoattractant protein, MCP-1 in disease 89–90
- Moral issues, European Biotechnology Directive 30
- Morpac Pharma Group Ltd, report 567
- MorphoSys AG, HTS for antibodies 536
- Mouse models
 - enhancer/suppressor genes 127
 - human disease gene discovery 123–128
 - mendelian inherited diseases 124–125
 - multigenic diseases 125–126
- mRNA
 - antisense oligonucleotides 4–5
 - RNA drug targets and 426–427

MTOR/FRAP protein kinases 475
 Multidrug resistance (MDR)
 antibiotics 74
 modulation by taxinine derivatives 289–290
 new antibiotics (CR) 398
 tumours, organelle pH role 32–38
 Multi-target libraries 187–188
 Mutagenesis, antibiotic-stimulated 77
 Mycophenolate mofenetil (MMF), psoriasis treatment 228
 Myocardial ischaemia
 GPIIb/IIIa-receptor antagonist therapy 558–559
 models 11–13
 Myo-inositol derivatives, PI-3-kinase inhibition 96
 Myriad Core System 270
 Myriad Personal Synthesizer 272

N

Naamidine, EGF receptor antagonist as natural antitumour agent 39
 Nateglinide 287
 National Laboratory for the Genetics of Israeli Populations 152
 Natural products
 biodiversity (CR) 449–451
 compatibility with HTS (CR) 451
 sources (CR) 449
 Nautilus system 269–270
 NB1011, for colorectal cancer 185
 Nerve growth factor (NGF), in Alzheimer's disease (CR) 150
 Neuprex™ 398
 Neurodegenerative diseases
 adenosine receptors 548
 excitotoxic-induced iNOS expression 292–293
 Neurofibrillary degeneration, in Alzheimer's disease 149 (CR), 276
 Neuropathology, Alzheimer's disease 276
 Neuropeptide YY₁-receptor antagonists 531
 Neuroprotection
 CM101 role in prevention of paralysis 53
 nitric oxide synthase inhibitors (CR) 49
 Neutral endopeptidase, in septic shock 211
 Neutrophils, response to lipopolysaccharide 211
 inhibition/control 218
 NewBiotics, colorectal cancer therapy 185

New technology 3
 combinatorial chemistry conference (CR) 8–9
 conference (CR) 249–250, 251–253, 538–539
 novel approaches for the new millennium 1–2
 proteomics 55–62
 reaping rewards 341–342
 NF- κ B transcription factor 472, 474
 activation 474
 inhibition 93–94, 216–217
 inhibitors 477
 Nicotine 490–492
 beneficial effects 490
 Nicotinic drugs
 applications 490
 nAChR agonists 491–492
 selectivity 490
 withdrawal 491
 Nicotinic receptors 490–492
 acetylcholine (nAChR) 490
 clinical applications 490–491
 functions 492
 subtypes and properties 490
 Nitric oxide 47–49, 243
 acute toxicity (CR) 49
 clinical applications (CR) 47–49
 deficiency 243–244
 disbalance in cardiovascular system 243–244
 DNA damage and cell death (CR) 48
 Euroconference (CR) 47–49
 increased with NMDA receptor activation 292
 inhaled (CR) 49
 modulators as therapeutic agents (CR) 49
 neutralizing compound, phase I clinical trial 9
 production in lipopolysaccharide response 218
 inhibition 218
 signalling (CR) 48
 supplementation 243–244
 targets (CR) 48
 Nitric oxide synthase 49
 conference (CR) 47–48
 gene therapy strategies (CR) 49
 inducible (iNOS), excitotoxicity-induced 292–293
 inhibitors 218, 243
 neuroprotection (CR) 49

Nitroheterocycles, as antimycobacterial agents 480–481
 Nitroquinolones, as antimycobacterial agents 480–481
 NMDA receptors
 activation and increased nitric oxide 292
 antagonist, NR1/2B 569
 NMR-based screening, combinatorial chemistry 532
 'Non-culturable' organisms, natural products from (CR) 450
 Non-polyglutamylatable agents, book review 493–494
 Non-robotic fluidic systems 269–270
 Non-steroidal androgen receptor agonist, novel 238–239, 386
 Non-steroidal anti-inflammatory drugs (NSAIDs), Alzheimer's disease 150 (CR), 280
 Non-xanthine adenosine A₁ receptor antagonist 333–334
 NS3 protease, inhibitors 521–524
 Nuclear factor of activated T cells (NFAT) 472, 474
 kinases 474–475
 Nuclease, resistance, antisense oligonucleotides 5
 Nucleic acid sequences, databases and rapid searching 483–484
 Nucleoside derivatives, antiviral activity 97
 Nucleotide analogs, telomerase inhibition 158
 Nucleotide inhibitors, for selective telomerase inhibition 158

O

Obesity, growth hormone secretagogues 503
 Oestrogen, in Alzheimer's disease (CR) 150
 Oestrogen receptor 458
 ligands 442
 Oleanic acid oligoglycosides, effect on gastric emptying 290
 Oligodeoxynucleotides, antisense 460–461
 Oligofingerprinting (CR) 52
 Oligonucleotides
 antisense *see* Antisense
 oligonucleotides
 first generation 562–563
 phosphorothioate 562–563
 second-generation antisense 563–564
 telomerase inhibition 159

- Olomoucine 476
 mechanism of action 462
- Omeprazole, chiral switches 319–320
- Omeprazole-like derivatives, osteoclast V-ATPase inhibition 166–167
- Oncogenes 459
- Ondansetron 469
- Online journals *see* Internet
- κ -Opioid-receptor antagonist, combinatorial libraries 239
- Opioid receptors
 adenosine interaction 549
 ligands 386
- Optics, image-based screening 403–404
- Oral hypoglycaemic agents
see Hypoglycaemic agents, oral
- Orbofiban 558
- Organelles
 acidification, blocking, drug resistance reversal 36
 acidification mechanism 36
 pH, role in tumour cell biology and drug resistance 32–38
- Organic chemistry
 automated synthesis tools 265–274
see also Automated synthesis
 convergent automated parallel synthesis 377
 parallel synthesis 378–380
- Organic compounds, automated synthesis 399–400
- Osteoclast V-ATPase inhibitors 140
 bafilomycin A₁ derivatives 168–169
 natural 165–166
 non-specific 165
 omeprazole-like derivatives 166–168
 other possible uses 171
 selective 163–172
 simplified bafilomycin derivatives 169–170
 synthetic 166
- Osteoporosis
 cathepsin K as drug target 441–442
 novel therapeutic agents 335
 osteoclast V-ATPase inhibitors 163
- Oxadiazole ring systems, metabolism 467–468
- Oxazoles, metabolism 467–468
- Oxazolidinones 186
- Oxidative stress, excitotoxicity-induced iNOS 292–293
- P**
- p21 gene transfer 461
- p27 gene transfer 461
- p38 protein kinases 472, 473
 inhibitors 94, 289, 476
- p53
 gene transfer 462
 importance in cell cycle 457
 as therapeutic target 462
- Paclitaxel, mechanism of action 462
- Pain
 adenosine receptors role 548–549
 nicotinic drugs 491
- Parallel processing
 combinatorial chemistry (CR) 8
 organic synthesis 378–380
- Parallel synthesis
 convergent automated 377–383
 organic chemistry 265–266
- Paralysis, prevention by angiogenesis inhibitor (CM101) 53
- Parkinson's disease
 adenosine receptors 546–547
 nicotinic drugs 490, 491
- Paroxetine 142
- Patents
 biological materials, Europe 29
 biotechnology, European directive 27–31
 complementary for enantiomer pairs 316–317
 enantiomer specification 316
 European biotechnology (CR) 301–302
 genomics and 134–138
 information access 451
 over-patenting in genomics 135–136
 precedents for chiral switches 315–316
 private sector 135–137
 public sector 137
 selection, chiral switches and 314–315
- PD098059, MAP kinase inhibitor 476, 477
- PE4, lipopolysaccharide antagonist 214, 215
- Pentapeptides, new combinatorial library screening method 386–387
- Pentoxifylline, signal transduction inhibitor 216
- Peptide, folding, simulation 153
- D-Peptide antigens 292
- Peptide nucleic acids (PNAs), telomerase inhibition 159
- Peptides
 antibiotic *see* Antibiotic peptides
 cell cycle as drug discovery target 461
 peptidomimetic protocols (BR) 454
- Peptidomimetics
 review of techniques (BR) 454
 sugar-based 386
- Peptidyl derivatives, proteasome inhibitors 189
- Peptidyl trifluoromethyl ketones 291
- Percutaneous transluminal coronary angioplasty (PTCA) 458, 461
- Perindopril 378
- Peroxisome proliferator-activated receptors (PPARs)
 actions 139
 PPAR γ agonists, optimization 239–240
 solid-phase synthesis of BRL49653 336
- Perprazole 319
- Personnel, workplace influence 182–183
- Pfizer, stock split 138
- PH, organelle, in tumour cell biology and drug resistance 32–38
- Pharma 2005: An Industrial Revolution in R&D* 3, 199, 393–395
- Pharmaceutical Documentation Ring 207
- Pharmaceutical industry
 biotechnology partnerships in Europe (CR) 302
 complacency, lack of vision and future prospects 198–199
 exploration of HTS databases 370–376
 innovation and workplace design 181–185
 issues relating to collaborations 488
 leaders in pharmacogenomics 105–107
 new developments/technologies 3
 novel approaches for new millennium 1–2
 organization of preclinical development structures (CR) 453
 performance targets 185
 pharmacogenomics paradigm (CR) 105–107
- PricewaterhouseCoopers (PWC) report 3
- productivity crisis (CR) 393–394
- running costs of drug discovery 181
- sales forecasts 3
- shareholders returns 3
- technology investment management 567

- Pharmacodynamics, pharmacogenetics and (CR) 106
- Pharmacogenetics
 drug development 151–152
 IBC conference and developments (CR) 6
 profiling (CR) 394
 proteomics and 151–152
- Pharmacogenomics 105–107
 Bio '98 (CR) 105–107
 IBC conference and developments (CR) 6
 industry leaders (CR) 107
 reasons for rapid development (CR) 106–107
- Pharmacokinetics
 AUC screening of compounds 232–235
 discovery–development interface 535
 high-throughput screening, positioning (CR) 452–453
 pharmacogenetics and (CR) 106
 screening of discovery compounds in rats 232–237
 technical developments (CR) 199–201
- Pharmacoproteomics 62
- PHAT algorithm 483–484
- α -Phenoxypropionic acid derivatives, chiral switches 316
- Pheromones, antibiotics as 75
- Phosphatidylinositol-3-kinase 475
 cancer target 96
 inhibition by 3-substituted myo-inositol derivatives 96
- Phosphatidylinositol (PI)-3-kinase related kinases 475–476
- Phosphodiesterase, inhibition 40–41, 216–217
- Phosphodiesterase 4 (PDE4), inhibitors 40
- Phosphodiesterase type 4, dual inhibition with MMP 290–291
- Phosphoinositide signalling 96
- Phospholipids, immobilization 176
- Phosphorothioate DNA oligomers, telomerase inhibition 159
- Photodynamic therapy
 biological response 508
 mechanism of action 507–508
 principles and clinical applications 507–517
- Photofrin® 508–509
- Photosensitizers 508–516
 clinical trials and manufacturers 509, 513
 second-generation 509–510
- Phthalocyanines, photosensitizers 514–515
- PI-3-kinase related kinases 475–476
- Piezoelectric dispensing 412
- Piezo Sample Distribution Robot 368–369
- PIKKs 475–476
- Pindolol 469
- Pioglitazone 284
- 3-(Piperazinylpropyl)indoles 333
- PK1 (HPMA–copolymer conjugate of doxorubicin) 540–541
- PK2 (doxorubicin-containing copolymer), cancer therapy (CR) 541
- Plant cultures, biodiversity increased by (CR) 449–450
- Plants
 antibiotic peptide resistance 256
 antibiotic peptides and 254–255
 medicinal (BR) 154
 selection for research (CR) 449
 varieties, European Biotechnology Directive 30–31
- Plastics, cancer therapy (CR) 540–541
- Platelet(s)
 adhesion, agents modifying 554
 aggregation, agents modifying 554
 antiplatelet agents *see* Antiplatelet therapies
 GPIIb/IIIa-receptor blockade effect 555–556
 procoagulant activity 556
 receptor, new motif 386
 role in vascular disease 553
- Platelet activating factor, antagonists 218
- PMEA (adefovir) 97
- Polarization, fluorescence 356–357
- Polyacrylamide gel electrophoresis (PAGE), two-dimensional, proteomics 130
- Polyglutamylolation 493
 importance 493–494
- Polyketides 345
 combinatorial biosynthesis 345–346
- Polyketide synthases 345–346
 genetic manipulation 345
- Polymer-assisted solution phase (PASP), purification method (CR) 8
- Polymer–drug conjugates, cancer therapy (CR) 540
- Polymeric macromolecules, anticancer therapy and (CR) 540–541
- Polymer supporting reagents, combinatorial chemistry (CR) 538
- Polymyxin B 213
- Population segmentation, genomic technologies in drug discovery (CR) 6
- Porphyces, photosensitizers 515–516
- PPDm2B, lipopolysaccharide antagonist 214, 215
- PPM18, signal transduction inhibitor 216
- Preclinical development
 acceleration (CR) 452–453
 organizational structure (CR) 453
- Predictive databases 468–470
- PricewaterhouseCoopers (PWC) report 3
- Process change, workplace design 183
- Prodigiosins 165
- Productivity crisis, pharmaceutical industry (CR) 393–394
- Prograf (tacrolimus), psoriasis treatment 227
- Proliferative diseases, cell cycle molecules as drug targets 457–458
- Propentofylline, in Alzheimer's disease (CR) 150
- Protease
 drugs targeting in HIV infections 387–388
 FRET-based assay 365
- Protease inhibitors
 antimicrobial peptides (CR) 397–398
 bacterial (CR) 397–398
 hepatitis C virus 521–524
 for HIV resistance 201–202
 library 387
- Proteasome 63, 188
 20S regulators 66–67
 20S subunits exchanges 66
 antigen presentation 191
 antigen processing manipulation 66–67
 inhibition 188–192
 as multicatalytic protease complexes 188–189
 structure and active sites 65–66
- Proteasome inhibitors 63–71
 antigen presentation and 191
 apoptosis induction/inhibition 191
 applications 191–192
 cell cycle blocking 191
 as a panacea? 192

- peptide-derived 68–69
 - peptidyl derivatives 189
 - selectivity/potency comparisons 70
 - Protegrins 397–398
 - Protein(s)
 - bioinformatics 200
 - disease-specific, identification 57–58
 - expression profiling 129–132
 - folding, simulation 153
 - immobilization 176
 - inhibition methods 422
 - large *see* Large protein therapeutics
 - localization monitoring, using green fluorescent protein 309
 - microchip-based detection (CR) 346–347
 - phosphorylation 472
 - systematic analysis *see* Proteomics
 - transduction domains 537, 538
 - Protein farnesyltransferase, inhibitors 95–96
 - Protein kinase 472–476
 - as anti-inflammatory targets 472–479
 - gene regulation 472–479
 - Protein kinase C (PKC)
 - activation, V-ATPases 166
 - inhibitors 229
 - Protein kinase inhibitors 216–217, 476–478
 - future prospects 478–479
 - novel 336
 - screening of focused libraries 478
 - structure-based drug design (SBDD) 478
 - Protein–protein interactions
 - products targeting 387–388
 - proteomics application 132
 - Proteograph analyses 57
 - Proteolysis 188
 - ubiquitin-dependent 189
 - Proteomes 57, 129
 - Proteomics 56–57, 103–104, 112
 - alternative techniques 132
 - applications 130–132
 - conference (CR) 6, 52, 249, 344
 - in drug discovery 55–62, 129–133
 - drug mode-of-action studies 59–61
 - drug toxicology studies 61–62
 - future prospects 132–133
 - identification of disease specific proteins 57–58
 - immunoprecipitation studies 59
 - pharmacogenetics and 151–152
 - signal transduction studies 59
 - target validation 59
 - technology 130
 - value 129–130
 - Protocol Systems Inc., development and supply contract lawsuit 495
 - Protonation, sequestration and secretion (PSS) hypothesis 35–36
 - Proton pump
 - target for bone resorption inhibitors 163
 - vacuolar, structure 164
 - Protoplasts, antibiotic resistance development 75
 - Psoriasis
 - pathogenesis 222
 - photosensitizers 516
 - Psoriasis treatment 222–231
 - anti-CD4, anti-CD11a and anti-IL-8 229
 - CTLA4-Ig 229
 - DAB₃₈₉ IL-2 228
 - immunosuppressives 226–228
 - IMPDH inhibitors 228
 - new therapies 229
 - vitamin A analogs 224–226
 - vitamin D₃ analogs 223–234
 - PSS hypothesis 35–36
 - Publishing, data analysis results 371–375
 - Purine products 482
 - Purines, cyclin-dependent kinase inhibitors 482
 - Purvalanol A 476
 - Puryltin™ 512
 - Pyrazoles, as novel D₄-receptor ligands 93
 - Pyrophosphatase, inorganic, as new antifungal drug target 24
- Q**
- Quantitative trait loci (QTL), multigenic diseases 125–126
 - Quercetin 476
 - Queries, packages for information retrieval 494–495
 - Quinione, photosensitizer 516
 - Quinpirole 325
- R**
- Ramoplanin 397
 - Ram Synthesizer 268
 - RANTES 84
 - RAPID algorithm 483
 - RAS farnesylation, inhibition 336–337
 - RAS proteins 336
 - Rats, rapid pharmacokinetic screening of discovery compounds 232–237
 - Reaction-block systems 265, 266–268
 - Reagent supply, new concepts 399
 - Receptors, assays, flow cytometry 175
 - 5 α -Reductase inhibitor 440–441
 - Renal system, adenosine receptors and 546
 - Repaglinide 287–288
 - Research, combined pharmaceutical projects 1
 - Research and development (R&D)
 - alliances, hepatitis C virus research 520–521
 - conference (CR) 343
 - costs and expenditure 3
 - exploration of HTS databases 370–376
 - functional genomics application 109
 - future prospects for 2005 (CR) 393–395
 - genomics and proteomics impact 103–104
 - increasing costs 221
 - laboratory/building design and innovation 181–185
 - paradoxes in progress (editorial) 198–199
 - revolution in and *Pharma 2005 report* 3
 - Resin beads, high-loading single resin beads 41
 - Respiratory disease, adenosine receptors 543–544
 - Restenosis
 - cell cycle drugs 458–459
 - prevention/treatment 462
 - Retinoblastoma protein (pRb) 457
 - gene transfer 461
 - Retinoic acid 224
 - high-affinity receptor antagonists 481
 - Retinoic acid receptors 224
 - Retinoids 481
 - Retinoid X receptor (RXR) 224
 - antagonists 481
 - vitamin D₃ receptor heterodimer 224
 - Reuters Business Insight, report 221, 332
 - Reverse transcriptase
 - HIV, X-ray crystallography 107–108
 - patents and lawsuits 495
 - Rheumatoid arthritis, CCR2 antagonists 90
 - Rhodamines, photosensitizers 515
 - Risperidone 467
 - Ritonavir 69

- RNA
- as drug target 422
 - in infections 425–426
 - small-molecule drugs binding to 420–422
 - as small-molecule drug target 420–429
 - splicing 52
 - targeting with small-molecules 427–428
 - see also* mRNA
- RNA-dependent RNA polymerase, hepatitis C virus 527
- RNAse H 563
- Robot-arm systems 268–269
- Robotics, organic chemistry 265–266
- Roche Diagnostics Systems, hepatitis C virus technology lawsuit 495
- Roche Molecular Systems, hepatitis C virus technology lawsuit 495
- Rolipram 40
- Roscovitine 462
- Rosiglitazone 284
- Roxifiban 558, 560
- RWJ68354, serine/threonine kinase inhibitor 477
- RWJ67657, serine/threonine kinase inhibitor 477
- S**
- Saccharomyces cerevisiae*
- automated assessment of genes 17–26
 - computer-aided target selection 17–26
 - genome 17–18
- Sapacin 256
- Sarcodictyin libraries 141
- SB203580
 - MAP kinase inhibitor 477
 - signal transduction inhibitor 216
- SB213068, non-thiazolidinedione insulin sensitizer 285
- SB214857 (Iotrafiban) 558, 560
- SB226882, serine/threonine kinase inhibitor 477
- SC102, serine/threonine kinase inhibitor 477
- SC5468A (Xemilofiban) 558, 560
- Schizophrenia, nicotinic drugs 490, 491
- Scintillation proximity, assay imaging 405–406
- Scotia Holdings plc, agreement 439
- Screening
 - combinatorial chemistry and molecular diversity (BR) 203
 - computational libraries 571
 - flow cytometry 174–175, 177, 179
 - imaging systems in 401–410
 - see also* Image-based screening
 - ion-channel targets 431–439
 - pharmacokinetic/metabolic, high-throughput (CR) 452–453
 - protein kinase inhibitor libraries 478
 - rapid pharmacokinetic, *in vivo* 232–237
 - in silico* 257–264
 - virtual 257–263
- SDZ281240, psoriasis treatment 227–228
- SDZ880431, lipopolysaccharide antagonist 214, 215
- SDZASM981, psoriasis treatment 227–228
- SDZMRL953, lipopolysaccharide antagonist 214, 215
- SEC14, as new antifungal drug target 24
- Selection invention, chiral switches 314–315
- Selection patents, chiral switches 314–315
- Selective infective phage (SIP) technology (CR) 52
- Selective serotonin reuptake inhibitors (SSRIs)
 - chiral switches 318–319
 - novel agents 142
- Senile plaques, in Alzheimer's disease (CR) 149
- Septic shock
 - mortality 209
 - pathogenesis 211–212
- Sequence databases, rapid searching 482–483
- Serial analysis of gene expression (SAGE) (CR) 51
- Serine proteases, inhibitors 291
 - convergent automated parallel synthesis 381–382
- Serine/threonine protein kinases 472
 - inhibitors 476–477
 - p38 kinase, new inhibitors 289
- Serotonin *see* 5-Hydroxytryptamine (5-HT)
- Serum amyloid P (SAP), lipopolysaccharide inactivation 213
- SH2 targeted ligands, high-affinity 442
- Sialidase inhibitor, influenza virus 531
- Sibrafiban 558, 560
- Side effects, animal models and 15
- Signalling
 - chemokines 85–86
 - MAP kinase cascades 473–474
 - nitric oxide (CR) 48
 - phosphoinositide 96
 - vitamin D₃ 224
 - see also* Signal transduction
- Signal transducers and activators of transcription (STAT) 472, 475
- Signal transduction
 - cascades, protein kinases 472–476
 - by lipopolysaccharide, inhibitors 216–217
 - proteomics use 59
 - see also* Signalling
- Simulation, biological
 - drug discovery 10–16
 - peptide/protein folding 153
- Simulation models, discovery–development interface 535
- Single nucleotide polymorphisms (SNPs)
 - conference 6
 - flow cytometry 177
 - patents 136
 - pharmaceutical company collaboration (CR) 344
- SK&F86002, serine/threonine kinase inhibitor 477
- Skin cancer, photosensitizer use 511
- Sleep
 - adenosine receptors role 548
 - enhancement, growth hormone secretagogues 504
- SMAD proteins 475
- Small-molecules, RNA as drug target 420–429
- Small Molecule Therapeutics, novel antibacterial agents 140
- Snakebite venomations, metalloproteinase inhibitors 532
- Software *see* Computer software
- Solid-phase synthesis
 - BRL49653 336
 - combinatorial chemistry conference (CR) 7
 - peptides (BR) 54
- Soluble guanylate cyclase (sGC), nitric oxide target (CR) 48
- Solution-phase synthesis, combinatorial chemistry conference (CR) 7
- Somatostatin-receptor ligands 532
- Spinal cord injury, angiogenesis inhibitor treatment 53
- Spiro-oxindoles, convergent automated parallel synthesis 382–383

SPLAT algorithm 483–484
 Split-mix libraries 539
 Spontaneously hypertensive rats 244
 State for São Paulo Research Foundation 349
 STAT family 472, 475
 Staurosporine 476
 Steroid reductase inhibitor 440–441
 Steroidal drugs, Alzheimer's disease 280
 Strategic alliances 207
 importance, report 221
 Strecker synthesis 539
 Stress
 antibiotic-perpetuated 77
 oxidative, excitotoxicity-induced iNOS 292–293
 Stroke, antiplatelet agents 554–555
 Structure–activity relationships,
 peptide/protein folding and 153
 Structure-based drug design (SBDD),
 protein kinase inhibitors 478
 Sugar-based peptidomimetics 386
 Sulfonylureas 286
 Sumatriptan 333, 469
 Superbugs, ways for defeating (CR)
 395–398
 Synercid® 397
 Syro II system 268
 Systemic lupus erythematosus (SLE),
 mouse models 126

T

Tacrolimus (FK506), psoriasis treatment 227
 Target identification
 flow cytometry 179
 proteomics application 130–131
 Targets *see* Drug targets
 Target validation *see* Validation
 τ proteins, in Alzheimer's disease (CR) 149
 Taxinine derivatives, multidrug resistance
 modulation 289–290
 Tazarotene 225–226
 psoriasis treatment 225
 T cells
 asthma pathogenesis 291
 CTLA4-Ig (CD28) 229
 cytotoxic, antigen presentation and
 proteasome inhibitors 63–71
 IL-2 expression and DAB₃₈₉ IL-2 fusion
 protein 228
 in psoriasis 228

Technologies, new *see* New technology
 Telomerase 155–161
 in cancer 156–157
 inhibitors 158–160
 applications 159–160
 design 157–158
 structure and subunits 155–156
 Telomeres 155
 Temoporfin, photosensitizer 512–514
 Testicular cells, increased susceptibility to
 chemotherapy 250–251
 Tetanus toxin inhibitors 291–292
 Tetrahydrobenzindoles, selective 5-HT₇-
 receptor antagonists 290
 Texaphyrins, photosensitizers 514
 Thalidomide 40
 (3-substituted benzyl)Thiazolidine-
 2,4-diones 335
 Thiazolidinedione insulin sensitizers
 283–284
 Thioester derivatives, of leinamycin 384
 Thrombin inhibitors 384–385, 556–557
 Thrombocytopenia, GPIIb/IIIa-receptor
 antagonists 560
 Thymidylate synthase, inhibitors 442–443
 Thymus-expressed chemokine (TECK) 299
 Tibotec NV, joint venture 264
 Tiludronate 167
 Tin etiopurpurin, photosensitizer 512
 Tirofiban 558
 Tobacco use 490
 Toll-like receptors 211
 Topoisomerase I, yeast, drug target 21–22
 Toxicity, discovery–development interface
 and 535
 Toxicology
 emerging technologies for accelerated
 evaluation (CR) 453
 evaluations in drug discovery (CR) 453
 proteomics application 61–62, 131–132
 technical developments (CR) 199–201
 Traditional medicine, medicinal plants (BR)
 154
 Transactivating regulatory proteins 537
 Transcription, cascades 472–474
 Transcription factors 472
 E2F 461
 importance in cell cycle 457
 NF- κ B *see* NF- κ B transcription factor
 Transcription reporter, green fluorescent
 protein (GFP) 306–308
 Transduction, large proteins 537

Transforming growth factor β (TGF- β), nitric
 oxide synthase inhibition 218
 Transgene (company), cervical cancer
 treatment 567
 Transgenic animals, IL-6 278
 Transplantation, rejection, chemokine
 receptor role (CR) 300
 Transposons, antibiotic regulated 73
 Trehalose phosphate synthase, as new
 antifungal drug target 24
Trends journals 197
 Trident system 271
 Trihydroxybenzamide derivatives 166
 Troglitazone 284
 Tropane analogues 329
 Tropisetron 469
 Tumour necrosis factor α (TNF- α)
 inhibitors 40
 response to lipopolysaccharide 217
 Tumours
 anticancer agent targeting (CR)
 540–541
 cell biology, organelle pH role 32–38
 drug resistance, organelle pH role 32–38
 see also Cancer
 Tumour suppressor, p53 and importance in
 cell cycle 457, 462
 Turn-mimetics, peptidomimetic protocols
 (BR) 454
 Two-hybrid system, yeast 132
 Tyrosine protein kinases 472
 Tyrphostins 463
 AG126, signal transduction inhibitor 216
 AG556, signal transduction inhibitor 216

U

U0126, serine/threonine kinase inhibitor
 477
 Ubiquitin 189
 Ubiquitin–proteasome pathway 188, 189
 actions 191, 192
 Ultra-high-throughput screening (UHTS)
 benefits 341–342
 conference (CR) 343
 miniaturized FRET assays and
 microfluidics 363–369
 Universities, spin-out companies 488–489
 US
 market growth for antidepressants 332
 Patent and Trademark Office (PTO) 135,
 136, 138
 patent law for chiral switches 315–316

V

Vacuolar H⁺-ATPases 163
inhibitors *see* Osteoclast V-ATPase
inhibitors
Validation
antisense oligonucleotides 562–567
antisense technology 564–566
cell cycle as target for drug discovery
460–463
drug targets
conference (CR) 51
proteomics use 59
models for drug discovery 15–16
proteomics application 131–132
Vancomycin-resistant enterococci 395
new antibiotics for 396–397
Vascular disease, platelets role 553
Vascular permeability, anticancer therapy
and (CR) 540
Vascular smooth muscle cells,
hyperproliferation 458–459, 460–461
Vasopressin, receptor antagonists 530
Vectors, antibiotic resistance transfer
75–76

Verteporfin, photosensitizer 511–512
Viral infections
cell cycle drugs 459
chemokines and (CR) 300
Virtual corpus, simulations for drug
discovery 13
Visualization, HTS databases 370–376
Vitamin A analogs, psoriasis treatment
224–226
Vitamin B₁₂, synthesis 379
Vitamin D₃ analogs, psoriasis treatment
223–234
Vitamin D₃ receptor (VDR) 223
agonists 223–224
Vitamin D₃ response elements (VDRE) 224
Vitravene™, FDA approval 4
VK19911, serine/threonine kinase inhibitor
477
VLA-4, inhibitors 186
VX497, psoriasis treatment 228
W
Websites 42–43
Well assay plates, 3456-well 363, 365, 366

Workplace, design and innovation 181–185
World Wide Web *see* Internet

X

Xenilofiban 558, 560
Xeroderma pigmentosum group A protein,
increased susceptibility to
chemotherapy 250–251
X-ray crystallography, HIV reverse
transcriptase 107–108

Y

Yeast
genome, computer-aided analysis 18
new drug targets 21–22
two-hybrid system 132

Z

Zafirlukast, associated drugs 39–40
Zenyx Magellen 267
ZK158252, leukotriene B₄-receptor
antagonist 229
Zonisamide 467
Zymark Benchmate arm system 269
Zymate XP radial arm system 268–269